Virologist Develops Experimental Vaccine Delivered via Beer

A virologist at the National Cancer Institute has developed an experimental beer intended to deliver vaccine-like effects against certain viruses. The beer incorporates engineered brewer's yeast that produces harmless viral proteins from BK polyomavirus, which can cause brain and cardiovascular diseases, particularly in individuals with compromised immune systems.

This method seeks to induce protective antibodies through oral consumption.

The virologist, Chris Buck, conducted the work independently of his agency. He published a non-peer-reviewed research article on the topic and contributed to a National Institutes of Health-supported study demonstrating related effects in mice. The study involved feeding engineered yeast to lab mice, which induced antibody responses against the virus.

Buck explained his motivation in a December post on Medium. He stated that he has homebrewed beer for 30 years and, upon learning of the mouse study results, decided to replicate the process at home. The engineered yeast produces proteins similar to those used in vaccines like the one for COVID-19, which trigger the immune system.

In an explanatory video on YouTube, Buck described the process. He said the yeast serves as a vehicle to protect the proteins from stomach acid, allowing them to reach the intestine where the immune system can detect them. This makes the yeast more effective than consuming pure proteins directly.

consumed one to two pints of the beer daily for five days, followed by two booster doses five and seven weeks later.

Blood tests after consumption showed production of antibodies against two strains of BK polyomavirus, which may contribute to bladder cancer. No significant side effects were reported during this self-administration. The approach targets viruses dangerous to people with weakened immune systems.

BK polyomavirus is a common infection that typically causes no symptoms in healthy individuals but can lead to complications in immunocompromised patients. The experimental beer aims to provide immunization through a familiar beverage, potentially addressing needle-related hesitancy.

U.S. has been linked to increases in measles and other preventable diseases. This method could offer an alternative delivery for vaccines, though it remains in early experimental stages. Broader application would require further safety and efficacy testing.

Buck launched a non-profit organization called the Gusteau Research Corporation to advance development of such vaccine molecules.

The organization focuses on producing and testing the beer as a private initiative. However, a research ethics committee at the National Institutes of Health initially advised against self-experimentation with the beer. In February, Buck was placed on paid administrative leave pending an investigation, as reported by Science News.

The details of the investigation were not specified, and Buck indicated plans to file a complaint. U.S. Food and Drug Administration processes overlook the medicinal properties of certain foods already in the supply.

Buck noted that if a substance is present in the food supply without known issues, it can be considered generally recognized as safe. He has discussed these points in interviews with The Times. Colleagues expressed concerns about potential impacts on public trust in science.

A virologist at the University of Michigan Medical School, Michael Imperiale, stated to Science News that the scientific community must consider whether such actions could increase public distrust. Imperiale emphasized the need for rigorous testing before any rollout. Buck reported that some individuals hesitant about traditional vaccines showed interest in this beer-based approach.

The experiment highlights ongoing efforts to innovate vaccine delivery methods amid rising hesitancy.

Traditional vaccines often require injections, which deter some people. Oral alternatives could expand access, but alcohol consumption, including beer, is associated with increased cancer risk according to federal data, with more than half of Americans drinking alcohol. Future steps may involve peer-reviewed studies and regulatory approval.

The non-profit's work could lead to trials for human use beyond self-administration. Monitoring for long-term effects and efficacy remains essential.